Literature DB >> 24615009

TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.

Hua-Jie Dong1, Cheng Fang, Li Wang, Lei Fan, Ji Xu, Jia-Zhu Wu, Ting-Xun Lu, Jian-Yong Li, Wei Xu.   

Abstract

Previous studies have investigated the associations between TP53 mutations and codon 72 polymorphisms and prognosis in chronic lymphocytic leukemia (CLL). However, the joint effect of TP53 mutations and TP53 codon 72 polymorphisms on CLL prognosis remains uncertain. We used direct sequencing to detect TP53 mutations and codon 72 genotype in 207 patients with CLL. The Pro/Pro genotype was associated with an increased incidence of TP53 mutations and deletion, but had no apparent effect on biological tumor behavior or clinical response. Compared to patients with wild-type p53, patients with TP53 mutations and the Pro72 allele (Arg/Pro + Pro/Pro genotypes) were associated with unmutated immunoglobulin heavy-chain variable region status and chemorefractoriness. Overall survival (OS) in the entire patient group was differed significantly between patients with TP53 mutations and either the Pro72 allele or Arg/Arg homozygotes (P = 0.014). Notably, patients with TP53 mutation and the Pro72 allele experienced a 23.7-fold increase in hazard ratio (95% CI 3.38-165.9; P = 0.001) for OS compared with patients with wild-type p53 and those with the Arg/Arg genotype. The TP53 Pro72 allele potentially increases the prognostic significance of TP53 mutations in CLL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615009     DOI: 10.1007/s12032-014-0908-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  39 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

3.  Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Johannes Bloehdorn; Sebastian Hafner; Andreas Bühler; Till Seiler; Dirk Kienle; Dirk Winkler; Markus Bangerter; Richard F Schlenk; Axel Benner; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2006-01-17       Impact factor: 44.544

Review 4.  How I treat refractory CLL.

Authors:  Emili Montserrat; Carol Moreno; Jordi Esteve; Alvaro Urbano-Ispizua; Eva Giné; Francesc Bosch
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

5.  Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients.

Authors:  N Barnabas; M Shurafa; D L Van Dyke; S R Wolman; D Clark; M J Worsham
Journal:  Cancer       Date:  2001-01-15       Impact factor: 6.860

Review 6.  To die or not to die: how does p53 decide?

Authors:  Elizabeth A Slee; Daniel J O'Connor; Xin Lu
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

7.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Authors:  Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

8.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.

Authors:  Wei Xu; Jian-Yong Li; Yu-Jie Wu; Hui Yu; Qiu-Dan Shen; Li Li; Lei Fan; Hong-Xia Qiu
Journal:  Leuk Res       Date:  2007-11-26       Impact factor: 3.156

Review 10.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

View more
  4 in total

1.  TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India.

Authors:  Raju S R Adduri; Rajender Katamoni; Ramaswamy Pandilla; Sandeep N Madana; Arun Kumar Paripati; Viswakalyan Kotapalli; Murali Dharan Bashyam
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 2.  ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Authors:  J Malcikova; E Tausch; D Rossi; L A Sutton; T Soussi; T Zenz; A P Kater; C U Niemann; D Gonzalez; F Davi; M Gonzalez Diaz; C Moreno; G Gaidano; K Stamatopoulos; R Rosenquist; S Stilgenbauer; P Ghia; S Pospisilova
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

3.  TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population

Authors:  Ameen Abdulaziz Mohammed Basabaeen; Enaam Abdalrhman Abdelgader; Ebtihal Ahmed Babekir; Saadia Osman Abdelrahim; Nada Hassan Eltayeb; Osama Ali Altayeb; Eman Abbass Fadul; Abdulwali Sabo; Ibrahim Khider Ibrahim
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

4.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.